On June 12, 2025, Nurix Therapeutics, Inc. announced updated results from their Phase 1 clinical trial of bexobrutideg (NX-5948) at the EHA2025 conference, showing an 80.9% objective response rate among participants with chronic lymphocytic leukemia or small lymphocytic lymphoma, who had extensive prior treatments. The treatment was well tolerated, with most patients continuing on it after a median follow-up of 9 months.